Loading company…
NeuroVenti develops treatments and research services for neurological and developmental disorders.
NeuroVenti develops treatments for developmental and neurological disorders, including NV01-A02 for autism spectrum disorder, and provides nonclinical research services. The Seoul-based company was founded in 2015 and led by Shin Chan-young. It raised KRW 1 billion in venture funding from HLB Investment and other unspecified investors in March 2024. The proceeds are intended to support clinical trials and development of its drug pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in